SAN DIEGO, Aug. 7, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it will present findings from the Phase II trial of MN-166 at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) and the 12th Conference of Rehabilitation in Multiple Sclerosis (RIMS). This joint meeting of the two societies will be held in Prague, Czech Republic, October 11 to 14, 2007.
